
A two-year DHA trial found no memory benefit over placebo. Learn what the results mean for supplement expectations and why they do not settle questions about fish.

On October 8, 2026, Medscape reported that a two-year trial of high-dose DHA found no advantage over placebo in cognitive-test results or hippocampal volume. The study tested whether this supplement could benefit adults with low fish consumption and elevated dementia risk.
A report describing the trial says the randomized, placebo-controlled study was published in eBioMedicine. It enrolled 365 adults aged 55 to 80. Participants received 2,000 mg of DHA daily or placebo.
People with and without the APOE4 genetic variant took part. Of those enrolled, 47% carried APOE4. Medscape reported that the results were similar regardless of APOE4 status.
After six months, cerebrospinal-fluid DHA rose by an average of 17% in the supplement group. Both reports described this increase, which showed that the intervention changed a DHA measure in the central nervous system.
This is biological target engagement. In plain language, the supplement had a measurable biological effect. That finding answers a question about what the intervention did inside the body.
After two years, the DHA group did not outperform placebo on memory or other cognitive tests. Imaging also showed no benefit for hippocampal volume, according to the reports.
These are separate findings, not contradictory ones. An intervention can change a biological measure without producing the hoped-for health outcome. For readers interested in memory protection, the cognitive-test results provide the more direct answer.
The placebo comparison is central to the conclusion. The relevant finding was not just whether DHA levels changed in the supplement group. It was whether the supplement group had better measured cognitive outcomes than the comparison group.
The timing also helps make the result clear. The reported DHA increase was seen after six months. The cognitive comparison covered the two-year trial. The earlier biological finding did not become evidence of a later memory advantage simply because more time had passed.
The practical change is in the evidence supporting the claim. This trial gives patients and clinicians a reason to question reliance on high-dose DHA alone as a proven cognitive-protection strategy.
A supplement taken for memory should be judged against evidence about memory, not just evidence that a biological measure changed. That keeps the reason for taking a product connected to the result being sought.
For adults 60+, the useful question is not whether a supplement sounds related to brain health. It is whether the tested intervention produced the benefit being sought. Here, that meant better performance on memory and other cognitive tests compared with placebo.
For someone reviewing a supplement with a clinician, a few questions can make the discussion more specific:
These questions do not require anyone to interpret a cerebrospinal-fluid test. They bring the discussion back to the intended benefit. A convincing explanation of how a product acts is not the same as evidence that it improves memory.
This is a reason for an evidence-based conversation, not an instruction to start or stop a supplement. Personal decisions about changing supplement use belong in a discussion with a qualified clinician.
It also helps to separate concern about memory from the appeal of a particular product. Understanding age-related changes in recall is one question. Assessing a supplement's cognitive effects is another. A trial result about the second should not become a judgment about a person's whole cognitive future.
The conclusion should stay tied to the tested intervention and the people enrolled. A high-dose DHA trial in this selected group does not settle every question about omega-3 use.
The study did not compare eating fish with taking a supplement. Its results therefore do not show that fish has no cognitive or other health value. Questions about dietary patterns and memory need food-based evidence rather than an assumption that a capsule trial answers them.
Nor does the trial establish that all omega-3 products, doses or durations produce the same outcome in every population. The finding also is not proof that the tested supplement was harmful. Lack of a measured benefit and evidence of harm are different conclusions.
For research, these boundaries are useful rather than inconvenient. They identify what was tested and keep the next question specific. A different study population or a combined intervention would need its own evidence rather than borrowing a positive claim from the DHA increase.
Medscape reported that researchers see further questions in studying people with early Alzheimer's disease or mild cognitive impairment. The coverage also raised testing DHA alongside other therapies as another research direction.
Those are proposals for further study, not proven ways to improve cognition. They explain where researchers may look next without establishing a new use for patients today.
This trial matters because it tested a specific supplement claim rather than relying only on a biological explanation. Researchers changed the DHA measure they were tracking, yet the cognitive and imaging results did not show the expected benefit.
For long-term cognitive health, that is a useful standard: ask whether a study measured an outcome that matters to the people taking the intervention. A biological finding deserves attention. It should not stand in for evidence about memory itself.
An unsuccessful supplement strategy also need not become a discouraging story about aging. Questions about routine, connection and purpose in retirement remain separate from this DHA experiment. Each deserves to be judged on its own evidence rather than grouped under a single promise of brain protection.
The lasting value of the study is clearer expectations. Progress in cognitive health requires more than a plausible mechanism or a changed laboratory measure. It requires evidence that an intervention delivers a meaningful benefit.
Supplement headlines can turn a laboratory change into an expectation about everyday memory, which is the confusion FitBrainLab works to avoid. For adults 60+ weighing which habits deserve attention, FitBrainLab translates research on nutrition and cognitive aging into practical guidance that separates findings from promises and makes uncertainty easier to understand.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.



Build habits that support memory, focus and a curious, connected life.
Read the Blog